London's AIM welcomes Arthro Kinetics:
This article was originally published in Clinica
Stuttgart, Germany-based orthopaedics company Arthro Kinetics has begun trading its shares on the Alternative Investment Market at the London stock exchange, following the placement of nearly 5 million shares priced at 120p ($2.10) each. Some £6m was raised in total from the public offering, proceeds which will be used to complete US clinical trials of the firm's cartilage regeneration system, CaReS, and advance its product pipeline (see Clinica No 1195, p 15). The company's market capitalisation at the placing price is £33m.
You may also be interested in...
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.